Definium Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

• Definium Therapeutics Inc reported a quarterly adjusted loss of 37 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -78 cents. The mean expectation of seventeen analysts for the quarter was for a loss of 56 cents per share. Wall Street expected results to range from -70 cents to -45 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Definium Therapeutics Inc's reported EPS for the quarter was a loss of 37 cents​.

• The company reported a quarterly loss of $50.96 million.

• Definium Therapeutics Inc shares had fallen by 12.6% this quarter and gained 148.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 5.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• Wall Street's median 12-month price target for Definium Therapeutics Inc is $70.00, about 52.5% above its last closing price of $33.27

This summary was machine generated from LSEG data November 9 at 10:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)